NATRELLE SILICONE-FILLED BREAST IMPLANTS
Allergan · Decision date Nov 17, 2006
What did the FDA approve?
FDA approval P020056, dated November 17, 2006, covers the Inamed silicone-filled breast implants, now listed under applicant Allergan. The decision statement describes the device as indicated for breast augmentation in women at least 22 years old and for breast reconstruction in women of any age. Augmentation is defined to include primary surgery to increase breast size and revision surgery to correct or improve a primary augmentation result.
Reconstruction is defined to include primary replacement of breast tissue removed due to cancer or trauma or that failed to develop properly due to a severe breast abnormality, plus revision surgery to correct or improve a primary reconstruction result. The statement reports the approved scope and purpose; it does not itself provide independent proof of safety or clinical effectiveness. No supplement type or reason is supplied, so no relationship to a prior PMA can be established from these fields.
FDA approval order statement
APPROVAL FOR THE INAMED SILICONE-FILLED BREAST IMPLANTS. THIS DEVICE IS INDICATED FOR BREAST AUGMENTATION FOR WOMEN AT LEAST 22 YEARS OLD AND FOR BREAST RECONSTRUCTION FOR WOMEN OF ANY AGE. BREAST AUGMENTATION INCLUDES PRIMARY BREAST AUGMENTATION TO INCREASE THE BREAST SIZE, AS WELL AS REVISION SURGERY TO CORRECT OR IMPROVE THE RESULT OF A PRIMARY BREAST AUGMENTATION SURGERY. BREAST RECONSTRUCTION INCLUDES PRIMARY RECONSTRUCTION TO REPLACE BREAST TISSUE THAT HAS BEEN REMOVED DUE TO CANCER OR TRAUMA OR THAT HAS FAILED TO DEVELOP PROPERLY DUE TO A SEVERE BREAST ABNORMALITY. BREAST RECONSTRUCTION ALSO INCLUDES REVISION SURGERY TO CORRECT OR IMPROVE THE RESULT OF A PRIMARY BREAST RECONSTRUCTION SURGERY.
- Regulatory pathway
- Original PMA
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Nov 17, 2006
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P020056
- Regulatory pathway
- Premarket approval application
- Applicant
- Allergan
- Product code
- FTR
- Decision code
- APPR
- Decision date
- Nov 17, 2006
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, breast, noninflatable, internal, silicone gel-filled.
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P020056 received
Application receipt date recorded by FDA.
P020056 · FDA decision
APPR
P020056/S064 · Related supplement
Natrelle Silicone-Filled Breast Implants and Natrelle INSPIRA Silicone-Filled Breast Implants
Timeline entries are records held by MedtechLedger for P020056. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P020056
Explore the linked device profile
Other records with product code FTR
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Sientra Silicone Gel Breast ImplantsP070004/S049 | Tiger Aesthetics Medical, LLC | PMA supplement | Nov 4, 2026 | FDA |
MemoryGel Breast ImplantsP030053/S093 | Mentor Corp. | PMA supplement | Oct 23, 2026 | FDA |
MemoryShape Breast ImplantsP060028/S063 | Mentor Worldwide, LLC | PMA supplement | Oct 23, 2026 | FDA |
| Motiva USA, LLC | PMA supplement | Oct 2, 2026 | FDA | |
| Motiva USA, LLC | PMA supplement | Sep 25, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Allergan
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2525 Dupont Dr., Irvine, CA, 92612
Sources and methodology
- Original FDA record: P020056
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



